Reid Huber joined Third Rock in 2018 as a Partner, bringing more than 25 years of leadership and experience to the role. He focuses on the formation, development, and strategy of Third Rockās portfolio companies. Reid served as Interim CEO of MOMA Therapeutics until the appointment of Dr. Asit Parikh in Spring of 2021, of Rapport Therapeutics until the appointment of Abe Ceesay in the Spring of 2023, and of Merida Biosciences until the appointment of Adam Townsend in the Spring of 2025.
Reid joined TRV from Incyte, where he was a member of the founding scientific team and most recently served as executive vice president and chief scientific officer. At Incyte, he held roles of increasing responsibility across multiple therapeutic areas in both drug discovery and clinical development. In 2011, he assumed responsibility for the companyās research and early development activities. Before joining Incyte, Reid held scientific research positions at DuPont Pharmaceuticals and Bristol-Myers Squibb from 1998 to 2002.
He received his Ph.D. in molecular genetics from the Washington University School of Medicine and held predoctoral and postdoctoral fellowships at the National Institutes āØof Health.
Reid is a board director at Rapport Therapeutics, Merida Biosciences, Terremoto, Synnovation Therapeutics, MOMA Therapeutics, Asher Biotherapeutics, and a board observer at insitro.
